LDX Shares Lumos Diagnostics Holdings Limited
ACCUMULATE ASX · ASXRespiratory-season adoption could accelerate utilisation of its point-of-care diagnostic platform.
Signal breakdown
- ▸US respiratory season provides near-term commercial catalyst.
- ▾Below 50-day MA (-36.72%)
- ▸Volume 13.11× average — accumulation
- ▾Near 52-week low (0% of range)
Is LDX a buy right now?
Trend: LDX is trading below the 50-day average (-16.00%), RSI 50 — neutral momentum, with a 3-month return of -23.64%.
Valuation & quality: Lumos Diagnostics Holdings Limited trades on forward P/E -6.0, price-to-book 2.46; fundamentals show net margin -37.5%, return on equity -34.1%, revenue growth 16.0% year on year.
Analyst consensus: 2 analysts have a mean 12-month price target of A$0.30 (+368.8% vs the last close; range A$0.25 – A$0.35), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Respiratory-season adoption could accelerate utilisation of its point-of-care diagnostic platform.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -17.90% | -26.10% | -29.40% | -16.70% | +0.00% | +0.00% | +0.00% | -20.00% |
Fundamentals
Analyst price target
Technical signals
About Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19.
Sector: Healthcare · Industry: Medical Devices · United States · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.